Literature DB >> 25040545

Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.

A M Huang1, B L Marini, D Frame, D M Aronoff, J L Nagel.   

Abstract

BACKGROUND: Recurrent Clostridium difficile infection (CDI) represents a significant burden on the healthcare system and is associated with poor outcomes in hematopoietic stem cell transplant (HSCT) patients. Data are limited evaluating recurrence rates and risk factors for recurrence in HSCT patients.
METHODS: HSCT patients who developed CDI between January 2010 and December 2012 were divided into 2 groups: non-recurrent CDI (nrCDI) and recurrent CDI (rCDI). Risk factors for rCDI were compared between groups. Rate of recurrence in HSCT patients was compared to that in other hospitalized patients.
RESULTS: CDI was diagnosed in 95 of 711 HSCT patients (22 rCDI and 73 nrCDI). Recurrence rates were similar in HSCT patients compared with other hospitalized patients (23.2% vs. 22.9%, P > 0.99). Patients in the rCDI group developed the index case of CDI significantly earlier than the nrCDI group (3.5 days vs. 7.0 days after transplant, P = 0.05). On univariate analysis, patients with rCDI were more likely to have prior history of CDI and neutropenia at the time of the index CDI case. Neutropenia at the time of the index CDI case was the only independent predictor of rCDI (78.8 vs. 34.8%, P = 0.006) on multivariate analysis.
CONCLUSIONS: The rate of rCDI was similar between HSCT and other hospitalized patients, and the majority of patients developed the index case of CDI within a week of transplantation. Neutropenia at the index CDI case may be associated with increased rates of rCDI.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  recurrence; recurrent Clostridium difficile; stem cell transplant

Mesh:

Year:  2014        PMID: 25040545     DOI: 10.1111/tid.12267

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  14 in total

1.  Transmission of Clostridium difficile During Hospitalization for Allogeneic Stem Cell Transplant.

Authors:  Mini Kamboj; Anna Sheahan; Janet Sun; Ying Taur; Elizabeth Robilotti; Esther Babady; Genovefa Papanicolaou; Ann Jakubowski; Eric Pamer; Kent Sepkowitz
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-21       Impact factor: 3.254

2.  Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.

Authors:  Wasef Na'amnih; Amos Adler; Tamar Miller-Roll; Dani Cohen; Yehuda Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-07       Impact factor: 3.267

3.  [Clostridium difficile infection : What is currently available for treatment?]

Authors:  A Stallmach
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 4.  Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?

Authors:  Mahmoud M Saleh; William A Petri
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

5.  Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.

Authors:  S Mani; L Rybicki; D Jagadeesh; S B Mossad
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 6.  Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.

Authors:  Edwin Vargas; Senu Apewokin; Rajat Madan
Journal:  Anaerobe       Date:  2017-02-20       Impact factor: 3.331

Review 7.  Neutrophil-mediated inflammation in the pathogenesis of Clostridium difficile infections.

Authors:  Shinsmon Jose; Rajat Madan
Journal:  Anaerobe       Date:  2016-04-05       Impact factor: 3.331

8.  Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Alex Ganetsky; Jennifer H Han; Mitchell E Hughes; Daria V Babushok; Noelle V Frey; Saar I Gill; Elizabeth O Hexner; Alison W Loren; Selina M Luger; James K Mangan; Mary Ellen Martin; Jacqueline Smith; Craig W Freyer; Cheryl Gilmar; Mindy Schuster; Edward A Stadtmauer; David L Porter
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

Review 9.  Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota.

Authors:  Alexander Khoruts; Keli L Hippen; Amanda M Lemire; Shernan G Holtan; Dan Knights; Jo-Anne H Young
Journal:  Transl Res       Date:  2016-07-25       Impact factor: 7.012

Review 10.  Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Elisa Balletto; Małgorzata Mikulska
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.